Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Pyxis Oncology ( (PYXS) ).
On July 1, 2025, Pyxis Oncology, Inc. announced the retirement of Pamela Connealy, their Chief Financial Officer and Chief Operating Officer. Her departure was amicable and not due to any disagreements with the company’s management or auditors. Following her retirement, Jitendra Wadhane, the current Senior Vice President Finance and Chief Accounting Officer, was appointed as the Principal Financial Officer. Mr. Wadhane will maintain his current roles without additional compensation.
The most recent analyst rating on (PYXS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Pyxis Oncology stock, see the PYXS Stock Forecast page.
Spark’s Take on PYXS Stock
According to Spark, TipRanks’ AI Analyst, PYXS is a Neutral.
Pyxis Oncology’s score reflects ongoing financial challenges with significant cash burn and unprofitability. While there are positive developments with the strategic focus on its lead candidate, technical indicators suggest caution. Valuation remains unattractive due to negative earnings. The company’s future hinges on successful execution of its strategic initiatives.
To see Spark’s full report on PYXS stock, click here.
More about Pyxis Oncology
Average Trading Volume: 568,404
Technical Sentiment Signal: Sell
Current Market Cap: $66.9M
See more insights into PYXS stock on TipRanks’ Stock Analysis page.